Geneva, Switzerland
Alcon, the global leader in eye care, boasts a robust history of over 75 years. Founded in 1945, this Swiss-based company operates at the intersection of Health Care, Manufacturing, and Medical Devices, with headquarters nestled in Switzerland.
With its expansive portfolio, Alcon develops innovative treatments that enhance sight and improve the quality of life for individuals with eye conditions such as cataracts, glaucoma, retinal diseases, and refractive errors. Serving more than 260 million people annually across 140 countries, the company relies on its 25,000+ associates to drive its mission forward.
Alcon's strategic focus on partnership with Eye Care Professionals and improving access to quality eye care has cemented its leadership position in the market. The company's most recent infusion of €500.00M in Post-Ipo Debt funding on 01 May 2022 underscores investor confidence in its sustained growth potential and innovation capacity.
